Lawrence Blatt discloses 5.6% stake in Aligos Therapeutics
Lawrence M. Blatt, who serves as president, chief executive officer, and director of Aligos Therapeutics, disclosed beneficial ownership of 316,228 shares, representing 5.6% of the company's outstanding common stock. Blatt stated he intends to review his investment on a continuing basis and may acquire additional securities, retain existing holdings, or sell shares in open market or private transactions. He also reserved the right to engage in discussions with management and the board regarding potential extraordinary corporate transactions, including mergers, asset sales, capital structure changes, and management changes.
Key facts
- Lawrence M. Blatt: 316,228 shares, 5.6% of class
- Reporting person serves as president, chief executive officer, and director
- Reserved right to pursue or encourage mergers, reorganizations, take-private transactions, asset sales, capitalization changes, and board/management changes
Why it matters
Blatt's disclosure of his substantial insider stake, combined with his explicit reservation of rights to pursue extraordinary transactions, signals potential strategic activity by the company's chief executive and board member.
Share
Derived from SCHEDULE 13D filed 2026-06-24. Not investment advice. View the source filing on SEC.gov →